Breaking News Instant updates and real-time market news.

NVS

Novartis

$86.95

2.49 (2.95%)

12:31
05/24/19
05/24
12:31
05/24/19
12:31

Novartis announces FDA approval for Zolgensma

  • 31

    May

NVS Novartis
$86.95

2.49 (2.95%)

05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
05/17/19
FBCO
05/17/19
NO CHANGE
Target $68
FBCO
Outperform
Alcon off to 'solid start' post-Novartis spin, says Credit Suisse
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on Alcon (ALC) and raised his price target to $68 from $66 following the company's quarterly results, saying Alcon is off to a "solid start" following the spinoff from Novartis (NVS), and says he is incrementally more bullish on the company's revenue and growth drivers.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.

TODAY'S FREE FLY STORIES

08:38
01/17/20
01/17
08:38
01/17/20
08:38
Conference/Events
Federal Reserve Board of Governors Vice Chairman speaks at a meeting »

Randal Quarles, Vice…

CSX

CSX

$76.75

1.76 (2.35%)

08:37
01/17/20
01/17
08:37
01/17/20
08:37
Recommendations
CSX analyst commentary  »

CSX price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:36
01/17/20
01/17
08:36
01/17/20
08:36
Conference/Events
Federal Reserve Bank of Philadelphia president participates in a discussion »

Federal Reserve Bank of…

IPIX

Innovation Pharmaceuticals

$0.00

(0.00%)

08:36
01/17/20
01/17
08:36
01/17/20
08:36
Hot Stocks
Innovation Pharmaceuticals announces dose escalation in Phase 1 trial »

Innovation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCDBF

CCL Industries

$0.00

(0.00%)

08:35
01/17/20
01/17
08:35
01/17/20
08:35
Hot Stocks
CCL Industries announces two bolt-on acquisitions for Avery »

CCL Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.62

0.695 (3.88%)

08:34
01/17/20
01/17
08:34
01/17/20
08:34
Recommendations
Gap analyst commentary  »

Gap price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

08:34
01/17/20
01/17
08:34
01/17/20
08:34
Conference/Events
UBS leisure analyst to hold an analyst/industry conference call »

Leisure, Gaming &…

PRGS

Progress Software

$47.54

2.25 (4.97%)

08:34
01/17/20
01/17
08:34
01/17/20
08:34
Recommendations
Progress Software analyst commentary  »

Progress Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHX

Panhandle Oil & Gas

$9.40

-0.02 (-0.21%)

08:33
01/17/20
01/17
08:33
01/17/20
08:33
Hot Stocks
Panhandle Oil & Gas appoints Interim CEO Chad Stephens as CEO »

Panhandle appointed Chad…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$46.86

0.56 (1.21%)

08:32
01/17/20
01/17
08:32
01/17/20
08:32
Recommendations
Comcast analyst commentary  »

JPMorgan sees 32M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

WMT

Walmart

$115.89

0.6 (0.52%)

08:30
01/17/20
01/17
08:30
01/17/20
08:30
Conference/Events
Cowen retail analyst to hold an analyst/industry conference call »

Retail Analyst Chen,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$19.99

(0.00%)

08:30
01/17/20
01/17
08:30
01/17/20
08:30
Options
One option delisting on January 17th »

Option delistings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPZ

Domino's Pizza

$287.30

-0.6 (-0.21%)

08:28
01/17/20
01/17
08:28
01/17/20
08:28
Recommendations
Domino's Pizza analyst commentary  »

Domino's Pizza price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OPRT

Oportun Financial

$23.09

0.19 (0.83%)

08:26
01/17/20
01/17
08:26
01/17/20
08:26
Downgrade
Oportun Financial rating change  »

Oportun Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:26
01/17/20
01/17
08:26
01/17/20
08:26
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

ESNT

Essent Group

$51.28

0.66 (1.30%)

08:25
01/17/20
01/17
08:25
01/17/20
08:25
Upgrade
Essent Group rating change  »

Essent upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACTT

Act II Global Acquisition

$10.15

-0.01 (-0.10%)

08:25
01/17/20
01/17
08:25
01/17/20
08:25
Conference/Events
Act II Global Acquisition management to meet with Odeon Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:24
01/17/20
01/17
08:24
01/17/20
08:24
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:24
01/17/20
01/17
08:24
01/17/20
08:24
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPGI

S&P Global

$298.16

3.86 (1.31%)

08:24
01/17/20
01/17
08:24
01/17/20
08:24
Downgrade
S&P Global rating change  »

S&P Global downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:24
01/17/20
01/17
08:24
01/17/20
08:24
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$202.88

2.07 (1.03%)

08:24
01/17/20
01/17
08:24
01/17/20
08:24
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$96.49

1.32 (1.39%)

08:23
01/17/20
01/17
08:23
01/17/20
08:23
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$59.51

0.08 (0.13%)

08:23
01/17/20
01/17
08:23
01/17/20
08:23
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$127.55

1.13 (0.89%)

08:23
01/17/20
01/17
08:23
01/17/20
08:23
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.